Technology area: Biotechnology & Pharmaceuticals
106 pending office actions • 54 art units • 95 examiners • 0 of 106 (0%) have an AI response strategy ready • 117 patents granted in the last 365 days
Hoffmann La-Roche Inc. maintains 1 pending office action in the Communications technology area. This matter is assigned to a distinct examiner working within 1 distinct art unit. GEBRESLASSIE, WINTA is the busiest examiner for this portfolio, currently overseeing the pending matter.
The presence of a single pending office action indicates a narrow prosecution window within the Communications sector. Because a single examiner is involved, the outcome of the current portfolio depends on the resolution of this specific action. This concentration allows for a targeted response strategy within the designated art unit.
Based on the USPTO statutory response window for each pending office action. 34 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 34 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 9 (8%) |
| §103 only | 18 (17%) |
| §102 only | 4 (4%) |
| §112 only | 14 (13%) |
| Double-patenting only | 7 (7%) |
| Double-patenting + other | 17 (16%) |
| Multi-statute (no §101) | 33 (31%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 4 | 65.8% | +53.6% |
| BRISTOL, LYNN ANNE | 3 | 63.4% | +39.8% |
| REILLY, SOPHIA JANE | 2 | 60.0% | +49.4% |
| NESTOR, DONNA MICHELLE | 2 | 56.6% | +44.2% |
| DEBERRY, REGINA M | 2 | 50.2% | +30.8% |
| MAHLUM, JONATHAN DAVIS | 2 | 50.0% | +23.3% |
| NICKOL, GARY B | 2 | 46.6% | +33.3% |
| DENT, ALANA HARRIS | 2 | 44.1% | +32.2% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
| KYU, TAYAR M | 1 | 40.5% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18150553 | Process for the preparation of oligonucleotides using modified oxidation protocol | LAU, JONATHAN S | 114d overdue |
| 18117966 | NOVEL HETEROCYCLIC COMPOUNDS | MCDOWELL, BRIAN E | 72d overdue |
| 18176062 | CRISPR/Cas9 MULTIPLEX KNOCKOUT OF HOST CELL PROTEINS | FLINDERS, JEREMY C | 53d overdue |
| 17186816 | METHOD FOR VERIFYING CULTIVATION DEVICE PERFORMANCE | MINCHELLA, KAITLYN L | 49d overdue |
| 18482264 | MACHINE LEARNING-BASED PREDICTION OF TREATMENT REQUIREMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) | SORRIN, AARON JOSEPH | 32d overdue |
| 18045037 | LARGE MOLECULE UNSPECIFIC CLEARANCE ASSAY | SVEIVEN, MICHAEL CAMERON | 23d overdue |
| 18888077 | MULTI-MODAL PATIENT REPRESENTATION | MACCAGNO, PIERRE L | 4d overdue |
| 17810426 | SINGLE-USE CELL CULTURE CONTAINER WITH ONE OR MORE IN-SITU ONLINE SENSORS | BOWERS, NATHAN ANDREW | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17507029 | THERAPEUTIC MULTISPECIFIC POLYPEPTIDES ACTIVATED BY POLYPEPTIDE CHAIN EXCHANGE | HUYNH, PHUONG N | 22d overdue |
| 17835261 | BRAF INHIBITORS AS PARADOX BREAKERS | MAHLUM, JONATHAN DAVIS | 19d overdue |
| 17507511 | ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE | HUYNH, PHUONG N | 11d overdue |
| 18280970 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF MYASTHENIA GRAVIS | NICKOL, GARY B | 20d |
| 17937440 | BISPECIFIC ANTIBODIES COMPRISING A MODIFIED C-TERMINAL CROSSFAB FRAGMENT | BRISTOL, LYNN ANNE | 34d |
| 18051307 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | BRISTOL, LYNN ANNE | 48d |
| 19667436 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | JOHANSEN, PETER N. | — |
| 19085993 | SUPPLY CHAIN OPTIMIZATION WITH REINFORCEMENT LEARNING | KYU, TAYAR M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 11 |
| 1627 | 6 |
| 1678 | 5 |
| 1641 | 5 |
| 1625 | 4 |
| 1626 | 4 |
| 1675 | 4 |
| 1624 | 4 |
| 1646 | 3 |
| 1644 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19667436 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | JOHANSEN, PETER N. | 1644 | §103DP | Non-Final OA | — | Pending | May 04, 2026 |
| 19085993 | SUPPLY CHAIN OPTIMIZATION WITH REINFORCEMENT LEARNING | KYU, TAYAR M | 3628 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 20, 2025 |
| 19050991 | MACHINE LEARNING ENABLED LOCALIZATION OF FOVEAL CENTER IN SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY VOLUME SCANS | HUYNH, VAN D | 2665 | §103 | Non-Final OA | — | Pending | Feb 11, 2025 |
| 19043123 | DIAGNOSTIC TOOL FOR REVIEW OF DIGITAL PATHOLOGY IMAGES | DESIRE, GREGORY M | 2676 | §102 | Non-Final OA | — | Pending | Jan 31, 2025 |
| 19010516 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | KUCHARCZK, JED A | — | §112 | Non-Final OA | — | Pending | Jan 06, 2025 |
| 18987316 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | HERNANDEZ, JACKSON J | 1627 | §103 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18875050 | OCT RETINAL VOLUMETRIC MEASUREMENTS BASED ON ETDRS GRID | ADEDIRAN, ABDUL -SAMAD A | 2621 | §102§103 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18965956 | METHOD FOR PRODUCING RECOMBINANT AAV PARTICLES | ABEYRATNE-PERERA, HASHANTHI KOMITIGE | 1633 | §102§103§112 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18865278 | NEW INDAZOLE DERIVATIVES | OTTON, ALICIA L | 1699 | DP | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18865274 | COMBINATION OF ALLOSTERIC AND ORTHOSTERIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18923478 | SEGMENTATION OF OPTICAL COHERENCE TOMOGRAPHY (OCT) IMAGES | GARCIA, SANTIAGO | 2673 | §103 | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18912379 | METHOD FOR DETERMINING AAV GENOMES | KIM, YOUNG J | 1681 | §103§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 18900301 | DETECTION OF GAIT ACTIVITY | ROBERTS, ANNA L | 3791 | §101 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18888077 | MULTI-MODAL PATIENT REPRESENTATION | MACCAGNO, PIERRE L | 3687 | §101§103 | Final Rejection | 4d overdue | Pending | Sep 17, 2024 |
| 18885056 | FORMS OF PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES, ITS FORMULATION AND ITS PROCESS OF MAKING | RAHMANI, NILOOFAR | 1691 | DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18844654 | COMBINATION THERAPIES FOR BREAST CANCER | REILLY, SOPHIA JANE | 1627 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18844371 | PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | FERGUSON, JALISA HOLMES | 1626 | §112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18816550 | PROCESSES FOR THE PREPARATION OF PHENYLTETRAHYDROFURAN COMPOUNDS | WHITE, DAWANNA SHAR-DAY | 1627 | §103 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18832840 | HETEROCYCLIC COMPOUNDS | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18777339 | Benzimidazole Pyridine Derivatives | CHANDRAKUMAR, NIZAL S | 1625 | §102§112 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18743437 | PROGNOSTIC MODELS FOR PREDICTING FIBROSIS DEVELOPMENT | YENTRAPATI, AVINASH | 2672 | §103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18741057 | MODULATION OF CELL GROWTH AND GLYCOSYLATION IN RECOMBINANT GLYCOPROTEIN PRODUCTION | STEADMAN, DAVID J | 1656 | §103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18672669 | QUANTIFICATION OF LOW AMOUNTS OF ANTIBODY SIDE-PRODUCTS | COUNTS, GARY W | 1678 | §112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18670375 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Final Rejection | — | Pending | May 21, 2024 |
| 18668810 | COMBINATION THERAPY OF ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES AND TYRP1-SPECIFIC ANTIBODIES | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103§112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18665776 | SYNTHESIS OF 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one | NESTOR, DONNA MICHELLE | 1627 | §103§112Other | Non-Final OA | — | Pending | May 16, 2024 |
| 18665390 | HETEROCYCLIC NLRP3 INHIBITORS | WILLIS, DOUGLAS M | 1624 | §102§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18659831 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV | KONOPKA, CATHERINE ANNE | 1635 | §102§103§112 | Non-Final OA | — | Pending | May 09, 2024 |
| 18657765 | CATALYTIC HYDROGENATION OF AROMATIC NITRO COMPOUNDS | CUTLIFF, YATE KAI RENE | 1692 | §102§112 | Non-Final OA | — | Pending | May 07, 2024 |
| 18653975 | USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER | RICCI, CRAIG D | 1611 | §103§112DP | Non-Final OA | — | Pending | May 03, 2024 |
| 18645245 | Method for purifying PEGylated erythropoietin | DEBERRY, REGINA M | 1647 | DP | Final Rejection | — | Pending | Apr 24, 2024 |
| 18702989 | CRYSTALLINE FORMS OF QUINAZOLINE DERIVATIVES, PREPARATION, COMPOSITION AND USE THEREOF | KOSTURKO, GEORGE W | — | §102§103§112Other | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18627727 | COMBINED ADMINISTRATION | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18626665 | CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | BAUER, BRIANNA LEE | 1623 | §112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18618124 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | MAHLUM, JONATHAN DAVIS | 1625 | §102§103§112DP | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18693273 | KIT FOR FORMING A MICROPLATE ASSEMBLY FOR ABSORBANCE MEASUREMENTS OF LIQUID SAMPLES | JARRETT, LORE RAMILLANO | 1797 | §103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18600323 | ANTI-TIM3 ANTIBODIES AND METHODS OF USE | BRISTOL, LYNN ANNE | 1643 | §102§112Other | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18581036 | METHOD FOR CLASSIFYING QUALITY OF BIOLOGICAL SENSOR DATA | DUONG, HIEN LUONGVAN | 2147 | §101§103 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18441878 | E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS | GORDON, MELENIE LEE | 1651 | §101§112 | Non-Final OA | 13d | Pending | Feb 14, 2024 |
| 18430887 | METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18292865 | PARTICLE COUNTER AND METHOD FOR COUNTING PARTICLES IN A STERILIZATION TUNNEL OF A MEDICAMENT FILLING SYSTEM | CHEN, CHANGRU | 1796 | §103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18424571 | METHOD FOR THE DETECTION OF ORGAN DERIVED EXTRACELLULAR VESICLES | MARCSISIN, ELLEN JEAN | 1677 | §103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18292242 | MEDICAL DELIVERY DEVICE | FORD, RENE D | 3741 | §102§112 | Final Rejection | 40d | Pending | Jan 25, 2024 |
| 18422786 | HALOACETHYDRAZIDES USEFUL AS AEP INHIBITORS | COLEMAN, BRENDA LIBBY | 1624 | §112 | Final Rejection | — | Pending | Jan 25, 2024 |
| 18542088 | SPATIAL ANALYSIS OF MITOTIC FIGURES IN HISTOPATHOLOGICAL IMAGES | AUGUSTIN, MARCELLUS | 2682 | §103 | Non-Final OA | 12d | Pending | Dec 15, 2023 |
| 18533714 | BISPECIFIC ANTI-CCL2 ANTIBODIES | NICKOL, GARY B | 1643 | DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18533539 | METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A PD-1 BINDING ANTAGONIST | DRISCOLL, MAUREEN VARINA | 1644 | §103§112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18526020 | IDENTIFICATION AND QUANTITATION OF RESIDUAL HOST CELL PROTEINS IN PROTEIN SAMPLES | LANKFORD JR, LEON B | 1657 | §103 | Final Rejection | — | Pending | Dec 01, 2023 |
| 18525536 | METHYLQUINAZOLINONE DERIVATIVES | MCKOY, QUINCY ANDRE | 1626 | §102 | Non-Final OA | 86d overdue | Pending | Nov 30, 2023 |
| 18506808 | LOGIC-BASED TYPING OF MULTIPLE SCLEROSIS SUBJECTS BASED ON CODED DATA | SKROBARCZYK III, ROBERT ANTHONY | 3792 | §101§103 | Final Rejection | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHoffmann-La Roche Inc. has 106 pending office actions as of October 2026, spread across 54 art units and 95 examiners.
Phuong N Huynh has the most, with 4 of Hoffmann-La Roche Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
